Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

27.59 -0.21 (-0.76%)
Streaming Delayed Price Updated: 3:38 PM EDT, Mar 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CG Oncology, Inc. - Common stock

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Pricing of Public Offering
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Proposed Public Offering
From CG Oncology Inc.
Via GlobeNewswire
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC 
From CG Oncology Inc.
Via GlobeNewswire
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress Posters 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
- First Patient Dosed in Expanded Access Program and Enrollment Ongoing - 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
- Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC - 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
3 attractive stocks that insiders are buying
The insiders are buying these attractive stocks. With a bank, a tech, a penny stock, a dividend payer, and a pharmaceutical winner, there is something for all. 
Via MarketBeat
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From CG Oncology, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.